Cyclo Therapeutics announces positive safety profile of its drug Trappsol Cyclo
Cyclo Therapeutics, Inc., a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Tag: Niemann Pick
Cyclo Therapeutics Presents Clinical Trial Data on Niemann-Pick Type C Disease
Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Carbohydrate drugs (Part 5) (Oligosaccharides, cyclodextrins)
First let’s talk about one of the biggest achievements in the history of cyclodextrin research: Sugammadex. Sugammadex (SGM) (BridionTM) (1a)
CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
Therapeutic potential for cyclodextrin‐based macromolecular systems in NPC
A paper has just come out in Macromolecular Rapid Communications highlighting the potential benefits of cyclodextrin-based macromolecular systems as cholesterol-mopping
HPBCD was tested for revealing the symptoms of Cockayne syndrome in mouse model: a surprise
Cockayne syndrome is a hereditary form of premature aging caused by a gene mutation. The disease affects more organs including
Advancements of CD analysis in Niemann-Pick C
Clearly, understanding the mechanism of action for cyclodextrins and consequently finding the most appropriate canditate for the treatment of Niemann
HPBCD can cross the Brain-Blood Barrier
Matencio et al. reported in their recent paper that 92.8% of HPBCD administered intrathecally to a child suffering from Niemann